Mohan Radhe, Das Indra J, Ling Clifton C
Department of Radiation Physics, MD Anderson Cancer Center, Houston, Texas.
Department of Radiation Oncology, New York University Langone Medical Center, New York, New York.
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):304-316. doi: 10.1016/j.ijrobp.2017.05.005.
Considering the clinical potential of protons attributable to their physical characteristics, interest in proton therapy has increased greatly in this century, as has the number of proton therapy installations. Until recently, passively scattered proton therapy was used almost entirely. Notably, the overall clinical results to date have not shown a convincing benefit of protons over photons. A rapid transition is now occurring with the implementation of the most advanced form of proton therapy, intensity modulated proton therapy (IMPT). IMPT is superior to passively scattered proton therapy and intensity modulated radiation therapy (IMRT) dosimetrically. However, numerous limitations exist in the present IMPT methods. In particular, compared with IMRT, IMPT is highly vulnerable to various uncertainties. In this overview we identify three major areas of current limitations of IMPT: treatment planning, treatment delivery, and motion management, and discuss current and future efforts for improvement. For treatment planning, we need to reduce uncertainties in proton range and in computed dose distributions, improve robust planning and optimization, enhance adaptive treatment planning and delivery, and consider how to exploit the variability in the relative biological effectiveness of protons for clinical benefit. The quality of proton therapy also depends on the characteristics of the IMPT delivery systems and image guidance. Efforts are needed to optimize the beamlet spot size for both improved dose conformality and faster delivery. For the latter, faster energy switching time and increased dose rate are also needed. Real-time in-room volumetric imaging for guiding IMPT is in its early stages with cone beam computed tomography (CT) and CT-on-rails, and continued improvements are anticipated. In addition, imaging of the proton beams themselves, using, for instance, prompt γ emissions, is being developed to determine the proton range and to reduce range uncertainty. With the realization of the advances described above, we posit that IMPT, thus empowered, will lead to substantially improved clinical results.
鉴于质子因其物理特性所具有的临床潜力,本世纪对质子治疗的兴趣大幅增加,质子治疗设备的数量也随之增多。直到最近,几乎完全采用被动散射质子治疗。值得注意的是,迄今为止的总体临床结果并未显示出质子治疗相对于光子治疗有令人信服的优势。随着最先进的质子治疗形式——调强质子治疗(IMPT)的实施,目前正在发生快速转变。在剂量学方面,IMPT优于被动散射质子治疗和调强放射治疗(IMRT)。然而,目前的IMPT方法存在诸多局限性。特别是,与IMRT相比,IMPT极易受到各种不确定性因素的影响。在本综述中,我们确定了IMPT当前存在的三个主要局限性领域:治疗计划、治疗实施和运动管理,并讨论了当前及未来的改进措施。对于治疗计划,我们需要减少质子射程和计算剂量分布中的不确定性,改进稳健的计划和优化,加强自适应治疗计划和实施,并考虑如何利用质子相对生物效应的变异性来实现临床获益。质子治疗的质量还取决于IMPT实施系统的特性和图像引导。需要努力优化子野光斑尺寸,以提高剂量适形性并加快治疗实施速度。对于后者,还需要更快的能量切换时间和更高的剂量率。用于引导IMPT的实时室内容积成像,如锥形束计算机断层扫描(CT)和轨道CT,尚处于早期阶段,预计会持续改进。此外,正在开发利用例如瞬发γ发射对质子束本身进行成像,以确定质子射程并减少射程不确定性。随着上述进展的实现,我们认为得到如此助力的IMPT将带来显著改善的临床结果。